<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To examine whether lowering of plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A randomized placebo-controlled double-blind study in 12 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were treated for 12 weeks after a 12-week dietary run-in </plain></SENT>
<SENT sid="2" pm="."><plain>Insulin sensitivity was assessed using a low-dose incremental intravenous insulin infusion </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="0" ids="5296">Gemfibrozil</z:chebi> significantly reduced fasting serum <z:chebi fb="0" ids="17855">triglyceride</z:chebi> concentrations (p &lt; 0.001) but had no effect on measures of diabetic control </plain></SENT>
<SENT sid="4" pm="."><plain>Neither <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> nor placebo treatment altered insulin sensitivity of <z:chebi fb="105" ids="17234">glucose</z:chebi> or <z:chebi fb="3" ids="17754">glycerol</z:chebi> metabolism during low-dose insulin infusion, but significant <z:hpo ids='HP_0002527'>falls</z:hpo> in both non-esterified fatty acid (NEFA) (p = 0.003) and <z:chebi fb="3" ids="17087">ketone</z:chebi> concentrations (p = 0.002) were observed after treatment with <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="5296">Gemfibrozil</z:chebi> does not affect insulin sensitivity to <z:chebi fb="105" ids="17234">glucose</z:chebi> or fat metabolism in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but enhances the lowering of plasma NEFA concentrations by insulin, probably by reducing hepatic fatty acid synthesis </plain></SENT>
</text></document>